Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.
Sanofi announces that it has successfully priced its offering of EUR 1.5 billion of notes across 2 tranches: • €850 million floating rate notes, due March 2027, bearing interest at 3-month Euribor ...
Global commodity trader Cargill plans to add 500 jobs to its global capability centres (GCCs) in the next two to three years, ...
Sanofi Indias standalone net profit jumped 31% Rs 91.3 crore in Q4 FY25 as compared with Rs 69.7 crore in Q4 FY24. Revenue increased 9.7% YoY to Rs 514.9 crore in Q4 FY25. Schaeffler Indias ...
William Pao, former Roche R&D leader and Pfizer CDO, now leads Revelio Therapeutics (formerly Launchpad) as CEO, joins ...
Flovie Martins joins Ujjivan Small Finance Bank as head of corporate communications. Prior to this, Martins was working with ...
Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...
Sanofi’s Sarclisa has received approval in more than 50 nations and regions. Credit: LCV/Shutterstock. Sanofi’s Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and ...
Earlier in her career, she was an Associate Principal at McKinsey & Company ... Prior to his time at Intercept, Mr. Durso spent over two decades at Sanofi, where he held multiple senior leadership ...
Sanofi and Teva’s inflammatory bowel disease candidate could make €1 billion ($1.05 billion) a year by 2032, Leerink analysts said on Sunday. The blockbuster pro ...
Gain valuable work experience at companies or organizations in your career field, Work in one of NYC’s cornerstone industries, Meet students from all over CUNY with similar interests as you, And earn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback